@misc{misc23cf9af6,
title   = {Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX + bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis},
author = {Peria, Fernanda Maris and Ungari, A. Q and Santos, F. N. Dos and Lins-Almeida, T. and Nunes, Altacílio Aparecido},
year = {2016},
doi = {10.1093/annonc/mdw387.29},
booktitle   = {Congress of European Society for Medical Oncology (ESMO)}
}